The pharma group has presented phase 1/2 results with new candidate NXT007 at the International Society on Thrombosis and ...

The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope ...

Around half of people diagnosed with pancreatic cancer will have been diagnosed with diabetes recently, according to NHS ...

A first look at the phase 3 data with Eli Lilly's oral GLP-1 agonist orforglipron reveals encouraging blood sugar control ...

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...

In early 2025, the White House renewed its push to lower prescription drug prices, part of an executive order aimed at easing patients' financial burdens. While the directive garnered headlines, many ...

Gilead is now waiting for regulatory decisions on the twice-yearly PrEP in Europe and other markets, including South Africa ...

The PMS requirement applies to all UKCA- and CE-marked devices, like in vitro diagnostics (IVDs), glucose monitors, and ...

EY's latest Biotech Beyond Borders report acknowledges the seismic changes in the US in the last few months, including cuts ...

IL-4 and IL-13 inhibitor Dupixent (dupilumab) is the first biologic drug to show an improvement in remission and symptoms in ...

Madrigal Pharma could be just weeks away from becoming the first drugmaker to claim EU approval for a treatment for metabolic ...

It has been reported that Novo Nordisk may have inadvertently allowed generics of its GLP-1 agonist semaglutide, the active ...